Breaking News
October 16, 2018 - Researchers demonstrate integrated technique to control production of cell therapeutics
October 16, 2018 - Breast tomosynthesis detects 34% more tumors than traditional mammography
October 16, 2018 - Rhode Island Hospital, Brown receive $800,000 grant to keep up fight against opioid epidemic
October 16, 2018 - Trevena Announces Oliceridine FDA Advisory Committee Meeting Outcome
October 16, 2018 - Study reveals early warning signs of heart problems in patients with newly diagnosed lupus
October 16, 2018 - Connecting the dots of Alzheimer’s disease
October 16, 2018 - New publication offers evidence-based content for global breast imaging medical community
October 16, 2018 - ‘EinsteinVision’ that improves hand-eye coordination of surgeons introduced at Harefield Hospital
October 16, 2018 - WRAIR clinical study evaluates safety and immunogenicity of Marburg vaccine
October 16, 2018 - Ketamine can be considered as alternative to opioids for short-term pain control in ED
October 16, 2018 - Endurance exercise training beneficially alters gut microbiota composition
October 15, 2018 - FDA Approves Yutiq (fluocinolone acetonide intravitreal implant) for Chronic Non-Infectious Posterior Segment Uveitis
October 15, 2018 - Birthing Options for Full-Term Pregnancy
October 15, 2018 - Stressed, toxic, zombie cells seen for first time in Alzheimer’s
October 15, 2018 - Concussion researchers study head motion in high school football hits | News Center
October 15, 2018 - Neuropsychiatric symptoms related to earliest stages of Alzheimer’s brain pathology
October 15, 2018 - Neck collar device may help protect the brain of female high school soccer players
October 15, 2018 - Research reveals how the inner ear processes speech
October 15, 2018 - Many parents still skeptical about safety and effectiveness of flu shot, survey finds
October 15, 2018 - Payer Policies May Discourage Non-Pharma Tx for Low Back Pain
October 15, 2018 - Exercise may delay cognitive decline in people with rare Alzheimer’s disease
October 15, 2018 - Researchers modify CRISPR to reorganize genome | News Center
October 15, 2018 - Innovative brain tumor operation set to tailor to patients’ needs
October 15, 2018 - Findings offer new insight into early changes that occur during AD pathology
October 15, 2018 - Neurons regulating reproductive hormone release have different activity in epileptic mice
October 15, 2018 - More parents are concerned about taking babies swimming in public pools
October 15, 2018 - Health Tip: Know the Risk Factors for Lower Back Pain
October 15, 2018 - Study shows cigarillo flavors enhanced by high-intensity sweeteners
October 15, 2018 - Study traces hospital-acquired bloodstream infections to patients’ own bodies | News Center
October 15, 2018 - Abnormal vision in childhood can affect development of brain areas responsible for attention
October 15, 2018 - Study highlights need for increased support for alcohol-related liver disease patients
October 15, 2018 - Color-changing contact lens could help doctors to monitor eye disease medications
October 15, 2018 - Tobacco heating products cause less staining to teeth than conventional cigarettes
October 15, 2018 - Young adults who are obese can expect to lose up to 10 years in life expectancy
October 15, 2018 - Scientists uncover how proteins meet on the cell membrane
October 15, 2018 - Affordable housing with supportive social services for senior citizens can reduce hospital use
October 15, 2018 - Schiller Easy Pulse Saves Lives
October 15, 2018 - The latest ECG device from Schiller
October 15, 2018 - Following a Tissue Sample
October 15, 2018 - Prisoners need drug and alcohol treatments but AA programs aren’t the answer
October 15, 2018 - Andrea Califano and Jordan Orange Elected to National Academy of Medicine
October 15, 2018 - The impending risk of African Swine Fever Virus
October 15, 2018 - Breastfeeding reduces the number of antibiotic-resistant bacteria in infant gut
October 15, 2018 - Researchers develop comprehensive molecular atlas of postnatal mouse heart development
October 15, 2018 - ObsEva SA Presents Clinical Data from Phase III IMPLANT 2 Trial of Nolasiban in IVF at the American Society of Reproductive Medicine (ASRM) Annual Meeting
October 15, 2018 - Engineering teratoma-derived fibroblasts to enhance osteogenesis
October 15, 2018 - Lab study shows effectiveness of potential therapy for treatment-resistant hypothyroidism
October 15, 2018 - JCU study firms up association between diet and depression
October 15, 2018 - Researchers to study the use of CRISPR on human liver on-a-chip platform
October 15, 2018 - Sub-concussive impacts not associated with decline in neurocognitive function
October 15, 2018 - Researchers find potential treatment to halt premature labor and birth
October 15, 2018 - As U.S. suicides rates rise, Hispanics show relative immunity
October 15, 2018 - FDA Issues a Complete Response Letter to Acacia Pharma for Barhemsys
October 15, 2018 - Photoactive bacteria bait may help in fight against MRSA infections
October 15, 2018 - Increasing vigorous exercise reduces risk factors of type 2 diabetes, cardiovascular disease in children
October 15, 2018 - First-of-its-kind study to test a personalized vaccine in cancer patient
October 15, 2018 - Extension trial assesses benefit of switching from flash monitoring to RT-CGM for hypoglycemia
October 15, 2018 - Half of parents say young children are afraid of doctor’s visits
October 15, 2018 - Study shows how fingerprint-based drug screening works on the living and deceased
October 15, 2018 - Study reveals potential to monitor progression of Alzheimer’s disease by measuring brain antioxidant levels
October 15, 2018 - FDA Approves Xarelto to Reduce the Risk of Major Cardiovascular Events in Patients with Chronic Coronary Artery Disease (CAD) or Peripheral Artery Disease (PAD)
October 15, 2018 - Promising new therapeutic approach against Ebola virus identified
October 15, 2018 - Study unravels how cancer stem cells use normal genes in abnormal ways
October 15, 2018 - Healthcare systems fail to deliver at affordable prices finds report
October 15, 2018 - Intensive BP Therapy in Diabetes May Lower Risk for CV Events
October 15, 2018 - Muscle relaxants increase risk of respiratory complications
October 15, 2018 - Female birds become more promiscuous after hatchings fail in the first breeding attempt
October 15, 2018 - Humans occupied Madagascar thousands of years later than previously thought
October 15, 2018 - Is Kidney Dialysis Always Needed When Septic Shock Strikes?
October 15, 2018 - Study shows invasive lung cancer surgery can lead to long-term opioid use
October 15, 2018 - Sugar, a “sweet” tool to understand brain injuries
October 14, 2018 - King’s commemorates activities and research on World Arthritis Day
October 14, 2018 - Humana and VFW NY team up on Stop 22 initiative to increase awareness of veterans committing suicide
October 14, 2018 - Water fluoridation contributes to urinary fluoride levels in pregnant women in Canada
October 14, 2018 - Study of children in Romanian orphanages tells cautionary tale about family separation
October 14, 2018 - Previous Endologix AFX Safety Notice classified by FDA as Class I recall
October 14, 2018 - Legal scholars sound alarm on academies’ report about returning research results to participants
October 14, 2018 - UNIST selects six extraordinary scholars to be induced as ‘Rising-star Distinguished Professor’
October 14, 2018 - Scientists find new way to help asthmatics breathe more easily
October 14, 2018 - New ‘gag rule’ may adversely impact health care of pregnant women
Clinical study uses genetic testing to match AML patients with new therapies

Clinical study uses genetic testing to match AML patients with new therapies

image_pdfDownload PDFimage_print

A clinical trial using genetic testing to match acute myeloid leukemia (AML) patients with new therapies is now open at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC). The center is one of seven cancer centers nationwide participating in the Beat AML® Master Trial, sponsored by the Leukemia & Lymphoma Society (LLS).

AML, which affects 20,000 Americans annually, is the most lethal of the blood cancers and is responsible for more than 10,000 deaths a year. Despite advances in treating other blood cancers, the standard treatment for AML – a combination of chemotherapies – has changed very little over the past 40 years. Overall prognosis remains poor, with a five-year survival rate below 20 percent for patients age 60 years and older.

“We are very pleased to be able to offer newly diagnosed AML patients age 60 years and older an opportunity to receive investigational drug therapies based on genetic markers associated with their subtype of AML,” says Maria R. Baer, MD, professor of medicine at the University of Maryland School of Medicine (UM SOM) and director of hematologic malignancies and co-leader of the experimental therapeutics program at UMGCCC. “This personalized therapy approach, employing genetic testing to help determine treatment, gives us a potentially powerful tool to fight this often deadly blood cancer.” Dr. Baer is the principal investigator for the study at UMGCCC.

UMGCCC is the latest cancer center to participate in the Beat AML clinical trial, which is designed to speed US Food and Drug Administration (FDA) approval of new drugs and develop more individualized, effective treatment approaches to the disease. LLS expects the trial will eventually include 500 patients at 15 to 20 sites.

Six other cancer centers are enrolling patients: Memorial Sloan Kettering Cancer Center; Ohio State University Comprehensive Cancer Center; Oregon Health & Science University Knight Cancer Institute; Harold C. Simmons Comprehensive Cancer Center at University of Texas Southwestern: University of Colorado Cancer Center: and University of Chicago Comprehensive Cancer Center. Six major biopharmaceutical companies – Alexion, Boehringer Ingelheim, Celgene, Gilead Sciences, Astellas and Takeda – are providing investigational therapies targeting specific gene mutations.

Newly diagnosed AML patients age 60 years and older are eligible to participate in the study, which is divided into nine treatment “arms.” Once patients are enrolled, their bone marrow is analyzed for genetic markers to help researchers determine the most appropriate treatment for their subtype of AML. Patients with no biomarkers are placed in a separate treatment arm, where they also receive an investigational therapy.

“Our faculty does outstanding research into hematologic malignancies and is engaged in many innovative clinical studies aimed at improving treatments for patients with AML and other blood cancers,” says UM SOM Dean E. Albert Reece, MD, PhD, MBA, executive vice president for medical affairs at the University of Maryland and the John Z. and Akiko K. Bowers Distinguished Professor. “This is a tremendous opportunity to collaborate with the LLS and other leading cancer centers on this important personalized medicine research initiative.”

Other leukemia clinical studies at the cancer center include a trial of a new combination drug therapy to treat AML, based on research done by a UMGCCC scientist; a trial of an immune modulator with chemotherapy for AML; and an immunotherapy trial using a patients’ own genetically altered immune cells, or T cells, to treat another form of leukemia, acute lymphoblastic leukemia, or ALL. UMGCCC is also a Center of Excellence for the treatment of myelodysplastic syndromes, a group of bone marrow disorders in which the bone marrow does not produce enough healthy blood cells.

Source:

http://www.umm.edu/programs/cancer/about-us/news/2017/beat-aml-master-trial

Tagged with:

About author

Related Articles